Table 1.
Morphometric data for PO studies
| Group | Treatment | n | RV Mass, mg | RV/BW, mg/g | LV Mass, mg | LV/BW, mg/g | BW, g | RV SP, mmHg | RV EDP, mmHg |
|---|---|---|---|---|---|---|---|---|---|
| No PAB | Vehicle | 6 | 133.8 ± 4.7 | 0.44 ± 0.01 | 560.2 ± 5.1 | 1.86 ± 0.01 | 301.1 ± 2.3 | 25.7 ± 0.7 | 5.4 ± 0.4 |
| No PAB | Rapamycin | 6 | 134.0 ± 1.4 | 0.45 ± 0.01 | 561.3 ± 6.9 | 1.90 ± 0.02 | 296.2 ± 1.4 | 26.5 ± 0.9 | 5.9 ± 0.3 |
| PAB | Vehicle | 5 | 201.0 ± 9.9* | 0.80 ± 0.04* | 561.9 ± 5.3 | 1.94 ± 0.01 | 259.1 ± 3.7 | 50.5 ± 1.7* | 7.4 ± 0.7* |
| PAB | Rapamycin | 6 | 168.9 ± 5.5*† | 0.60 ± 0.02*† | 514.8 ± 8.5 | 1.94 ± 0.03 | 266.1 ± 2.9 | 51.6 ± 1.3* | 7.6 ± 0.4* |
Values are means ± SE.
*
P < 0.05 vs. corresponding No pulmonary artery banding (PAB) group;
†
P < 0.05 vs. corresponding PAB + vehicle group. PO, pressure overload; RV, right ventricle; BW, body weight; LV, left ventricle; SP, systolic pressure; EDP, end-diastolic pressure.